Under the terms of the proposed merger agreement, Avocent shareholders will receive $25 in cash for each share of Avocent common stock they own for a total transaction value of $1.2 billion.  One analyst has given a $27 per share target price for the Company's stock. 

The investigation is focused on the potential unfairness of the consideration to Avocent shareholders and the process by which the Avocent Board of Directors is addressing the transaction.   The Avocent Board of Directors has agreed to a $35 million termination fee and/or reimbursement of transaction expenses to Emerson up to $7.5 million. 

If you are interested in discussing your rights as an Avocent shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at This email address is being protected from spam bots, you need Javascript enabled to view it .